

## amp biosimilars AG <sup>\*5a,11</sup>

**Rating: BUY**  
**Target Price: €40.30**

Current Price: 15.45  
21/09/2015 / MCH / 8:10am  
Currency: EUR

### Key Information:

ISIN: DE000A0SMU87  
WKN: A0SMU8  
Ticker symbol: 1YA  
Number of shares<sup>3</sup>: 2.05  
Marketcap<sup>3</sup>: 31.67  
EnterpriseValue<sup>3</sup>: 31.64  
<sup>3</sup> in mEUR  
Freefloat: 20.0 %

Transparency level:  
Freiverkehr  
Market segment:  
Börse München  
Accounting standard:  
HGB

Financial year-end: 31.12

### Analysts:

Cosmin Filker  
filker@gbc-ag.de

Manuel Hölzle  
hoelzle@gbc-ag.de

\* catalogue of potential conflicts of interests on page 7

Date of completion/ Date of publication:  
21/9/2015 / 21/09/2015

### Company Profile


Sector: Biotechnology  
Focus: Development and licensing of biosimilars

Employees : 10 As at : 1/4/2015

Founded : 2008

Registered Office : Hamburg

Executive Board : Dr. Hentz (CEO), G.Janssen ( CFO),  
Dr. Adermann (CTO), G. McGettigan (COO)



The focus of amp biosimilars AG, which was founded in 2008 and has been listed on the Munich Stock Exchange since 1 April 2015, is the development of high-quality biosimilars. In the financial year 2014, key moves were made both in the area of core competences and in the selection of suitable product candidates. While suitable employees could be found, the company carried out preparatory work on developing cell lines and cell banks in the development of biosimilars. Alongside this, amp biosimilars AG held negotiations on potential joint venture deals and business partnerships to ensure the funding for the product pipeline. In this regard, amp biosimilars AG has already licensed the first two projects to Chinese pharmaceutical companies. The development of biosimilars gives the company direct access to an industry characterised by strong momentum. Particularly in light of the progressing discontinuation of patents for originator products (reference products for manufacturing biosimilars), the market for biosimilars should show strong growth in the next few years. The platform approach allows amp biosimilars AG to develop biosimilars more cheaply, efficiently and quickly than was previously possible.

P&L in EUR m	2015e	2016e	2017e	2018e	2019e	2020e
Sales	0.00	0.00	0.14	0.72	13.14	31.06
EBITDA	-1.37	-3.16	-4.86	-7.03	6.96	24.78
EBIT	-1.37	-3.16	-4.86	-7.04	6.92	24.05
Net profit / loss	-1.37	-3.16	-4.86	-7.04	5.82	20.66

Per Share Figures in EUR	2015e	2016e	2017e	2018e	2019e	2020e
EPS	-0.67	-1.54	-2.37	-3.43	2.84	10.08

Key Figures	2015e	2016e	2017e	2018e	2019e	2020e
EV/Sales	n.def.	n.def.	225.98	43.94	2.41	1.02
EV/EBITDA	-23.07	-10.02	-6.51	-4.50	4.55	1.28
EV/EBIT	-23.09	-10.01	-6.51	-4.49	4.57	1.32
P/B	-23.12	-10.02	-6.52	-4.50	5.44	1.53

### Financial dates

### \*\*last research published by GBC:

Date: publication/price target in €/Rating

14/7/2015: RS / 40.30 / BUY

\*\* the research reports can be found on our website [www.gbc-ag.de](http://www.gbc-ag.de) or can be requested at GBC AG, Halderstr. 27, D-86150 Augsburg

## Executive Summary

### Half-year figures 2015 on target; target price and rating confirmed

- **Performance in the first half of 2015 did meet expectations**

As expected, the operating performance of the first six months of 2015 at amp biosimilars AG represented a period without turnover, resulting in a net loss of €0.60 million. A decisive factor therein was expenditure in connection with the stock exchange listing carried out in the first half of 2015, as well as expenditure linked to the out-licensing of the first two biosimilar development projects.

- **An important milestone reached thanks to the out-licensing of two projects**

In the first half of 2015, amp biosimilars AG was focussed on out-licensing projects as well as the developing and expanding of processes and the organisation. Our first ever out-licensing of two projects to a Chinese partner represented a particularly important milestone for us, and it shows the company's strategy which will also be applied to future projects, as they are to be out-licensed in an early stage of development. This brings the advantage that the comprehensive costs of clinical development are borne by the license partners.

- **Lower liquidity requirements due to early out-licensing**

Building on the foundation established in the first six months of 2015, amp biosimilars AG is expected to be able to identify further development candidates. We expect to begin preclinical development of four additional biosimilars before 2017. The financial requirements of the company are considered as low in the context of early out-licensing.

- **Significant turnover and income contribution expected in 2019**

The expectation is that amp biosimilars AG will achieve its first turnover in 2017. With the first sale of distribution rights for biosimilar projects expected in the financial year 2019, a corresponding income contribution is also expected to be attained. In principle, the business model of amp biosimilars AG is highly scalable.

- **Confirmation of the target price of €40.30, "BUY" rating**

Since assumptions have remained unchanged in comparison with the previous research study (see Initial Coverage Study of 14/07/2015), thus confirming forecasts, we have kept the DCF valuation model unchanged. We thereby confirm the previous target price of €40.30 per share and renew the "BUY" rating.

## Business development as at 30/06/2015

During the first six months 2015 amp biosimilars AG was focussed on out-licensing projects as well as the developing and expanding of processes and the organisation. Furthermore the listing of the amp-share at the Freiverkehr of the Börse München took place in April 2015.

Besides, during the HY1 2015 a concentration on human resources was undertaken. Now the company unites a wide know-how in the area of biosimilar development within the management board. With the Scientific Board, which currently consists of three members, the amp biosimilars AG gets an active support for the world-wide commercialisation-strategy as well as in the field of scientific and regulatory processes.

On that basis the amp biosimilars AG in the HY1 2015 had the ability to successfully out-license two biosimilar development projects in the areas oncology and immunology to a Chinese pharmaceutical-company. The strategy of an early out-licensing brings the advantage that the comprehensive costs of clinical development are borne by the license partners. As well the Chinese market, as so called Pharmerging Market, deems to be very interesting, in particular because of the high growth-rates in the pharmaceutical segment. According to IMS Health China as one of the strongest growing markets in the world will show an annual growth-rate of 16.7 % until 2017. Furthermore with biosimilars new patient groups are developed in the pharmerging markets, for which the treatment with patented and expensive reference drugs is too cost intensive.

As expected, the operational development of the amp biosimilars AG during the first six months 2015 was affected by lacking sales due to the still early development stage of the amp-projects, causing a negative earnings-situation. The net loss by 30/06/2015 was €0.60 million and is substantially affected by the expenses in conjunction with the listing on the stock market as well as the out-licensing of the first two projects. As of 30/06/2015 the company holds a cash position of €1.45 million.

## Forecasts and Model Assumptions

in €m	FY 2015e	FY 2016e	FY 2017e	FY 2018e	FY 2019e	FY 2020e
Sales	0.00	0.00	0.14	0.72	13.14	31.06
EBIT	-1.37	-3.16	-4.86	-7.04	6.92	24.05
Net profit or loss	-1.37	-3.16	-4.86	-7.04	5.82	20.66


Source: GBC AG

The basis for our turnover and result forecasts for future financial years is the project pipeline and the associated marketing timescale developed by us, while taking into account other biosimilar developments. The marketing turnover derived from this, yet only expected from 2019, is the key driver of revenue. amp biosimilars AG is also set to collect upfront fees as part of the additional planned licensing of product candidates and the regional expansion of licence contracts that have already been concluded. We also considered the option of a complete sale of the products as a basis for our turnover forecasts, where we assumed a potential sale at a more advanced stage of development, with correspondingly high revenues.

By 2017, we expect the identification and the start of the preclinical development of four additional biosimilar candidates, meaning that the product pipeline will then be expanded to a total of eight. It is notable that the current Chinese licence partner has signalled interest in a significantly higher number of biosimilar developments. amp biosimilars AG is also in discussions regarding additional partnerships, meaning that new licence

partners could be envisaged even for the current financial year 2015. Based on our assumptions, the following development schedule (preclinical and clinical) has been worked out, taking into account the planned expansion of the project pipeline:


**Project schedule of amp biosimilars AG**



Source: amp biosimilars AG; GBC AG

For our turnover forecasts, we assume early licensing of projects in the preclinical development stage, similar to the licences already in place. As we assume that licence partners will take over the funding for the clinical trials, the financial requirements for amp biosimilars AG are deemed low. This should also be the case for potential joint venture partnerships in which the partner company takes on the majority of the financing for the clinical trial. Under this strategy, amp biosimilars AG should receive a small amount of upfront payments and milestone payments at the point of licensing and depending on the development progress of the products.


**Sales forecasts (in € million)**



Source: GBC AG

As expected, amp biosimilars AG will still generate negative operating results in coming financial years (until 2019) due to the continued lack of any notable revenue. It is only once the expected first sale of distribution rights for biosimilar projects in the financial year 2019 has taken place that corresponding profit contributions will be generated. However, amp biosimilars AG’s business model, with revenue consisting of licensing revenue or revenue from the sale of distribution rights, is highly scalable. This means that an increase in the sales base is accompanied by an increase in earnings. With an expected steady growth of the cost base, even EBIT margins of over 80.0% are possible, which we also suggested as a long-term target figure in our DCF valuation model.

**Forecasted EBIT (in € million) and EBIT-margin (in %)**



Source: GBC AG

Based on EBIT, total financial requirements of €16.43 million have been forecasted until the end of the financial year 2018 or until break-even is reached. According to company data, various funding options may be taken. For example, a major shareholder made a funding commitment. Various capital market instruments, both of a debt or an equity nature, could also be issued. There are currently no specific plans for this yet.

**Since assumptions have remained unchanged in comparison with the previous research study (see Initial Coverage Study of 14/07/2015), thus confirming forecasts, we have kept the DCF valuation model unchanged. We thereby confirm the previous target price of €40.30 per share and also, consequently, the “BUY” rating based on a current share price of €15.45.**

## ANNEX

### **Section 1 Disclaimer and exclusion of liability**

This document is intended solely for information purposes. All data and information in this study come from sources that GBC regards as reliable. In addition, the authors have taken every care to ensure that the facts and opinions presented here are appropriate and accurate. Nevertheless, no guarantee or liability can be accepted for their correctness – whether explicitly or implicitly. In addition, all information may be incomplete or summarised. Neither GBC nor the individual authors accept liability for any damage which may arise as the result of using this document or its contents, or in any other way in this connection.

We would also point out that this document does not constitute an invitation to subscribe to nor to purchase any securities and must not be interpreted in this way. Nor may it nor any part of it be used as the basis for a binding contract of any kind whatsoever, or be cited as a reliable source in this context. Any decision relating to the probable offer for sale of securities for the company or companies discussed in this publication should be taken solely on the basis of information in the prospectuses or offer documents which are issued in relation to any such offer.

GBC does not provide any guarantee that the indicated returns or stated target prices will be achieved. Changes to the relevant assumptions on which this document is based can have a material impact on the targeted returns. Income from investments is subject to fluctuations. Investment decisions should always be made with the assistance of an investment advisor. This document cannot replace the role of an advisor.

### **Sale outside the Federal Republic of Germany:**

This publication, if sold in the UK, may only be made available to those persons who, in the meaning of the Financial Services Act 1986 are authorised and exempt, or persons as defined in section 9 (3) of the Financial Services Act 1986 (Investment Advertisement) (Exemptions) Decree 1988 (amended version) and must not be transmitted directly or indirectly to other persons or groups of persons.

Neither this document nor any copy of it may be taken into, transferred to or distributed within the United States of America or its territories and possessions. The distribution of this document in Canada, Japan or other jurisdictions may be restricted by law, and persons who come into possession of this publication should find out about any such restrictions and respect them. Any failure to respect these restrictions may represent a breach of the US, Canadian or Japanese securities laws or laws governing another jurisdiction.

By accepting this document you accept all disclaimers of liability and the restrictions cited above.

You can find the details of this disclaimer/exclusion of liability at:

<http://www.gbc-ag.de/de/Disclaimer.htm>

### **Legal information and disclosures as required by section 34b para. 1 of Securities Trading Act (WpHG) and Financial Analysis Directive (FinAnV)**

This information can also be found on the internet at the following address:

<http://www.gbc-ag.de/de/Offenlegung.htm>

### **Section 2 (I) Updates**

A detailed update of the present analysis/analyses at any fixed date has not been planned at the current time. GBC AG reserves the right to update the analysis without prior notice.

### **Section 2 (II) Recommendation/ Classifications/ Rating**

Since 1/7/2006 GBC AG has used a 3-level absolute share rating system. Since 1/7/2007 these ratings relate to a time horizon of a minimum of 6 to a maximum of 18 months. Previously the ratings related to a time horizon of up to 12 months. When the analysis is published, the investment recommendations are defined based on the categories described below, including reference to the expected returns. Temporary price fluctuations outside of these ranges do not automatically lead to a change in classification, but can result in a revision of the original recommendation.

**The recommendations/ classifications/ ratings are linked to the following expectations**

BUY	The expected return, based on the derived target price, incl, dividend payments within the rel 10 %.
HOLD	The expected return, based on the derived target price, incl, dividend payments within the rel 10 % and < + 10 %.
SELL	The expected return, based on the calculated target price, incl, dividend payments within the <= - 10 %.

GBC AG's target prices are determined using the fair value per share, derived using generally recognised and widely used methods of fundamental analysis, such as the DCF process, peer-group benchmarking and/or the sum-of-the-parts process, This is done by including fundamental factors such as e.g. share splits, capital reductions, capital increases, M&A activities, share buybacks, etc.

**Section 2 (III) Past recommendations**

Past recommendations by GBC on the current analysis/analyses can be found on the internet at the following address:

<http://www.gbc-ag.de/de/Offenlegung.htm>

**Section 2 (IV) Information basis**

For the creation of the present analysis/analyses publicly available information was used about the issuer(s) (where available, the last three published annual and quarterly reports, ad hoc announcements, press releases, share prospectuses, company presentations, etc.) which GBC believes to be reliable, In addition, discussions were held with the management of the company/companies involved, for the creation of this analysis/these analyses, in order to review in more detail the information relating to business trends.

**Section 2 (V) 1. Conflicts of interest as defined in section 34b para. 1 of the Securities Trading Act (WpHG) and Financial Analysis Directive (FinAnV)**

GBC AG and the analysts concerned hereby declare that the following potential conflicts of interest exist for the company/companies described, at the time of this publication, and in so doing meet the requirements of section 34b of the Securities Trading Act (WpHG), A detailed explanation of potential conflicts of interest is also listed in the catalogue of potential conflicts of interest under section 2 (V) 2.

**In relation to the security or financial instrument discussed in this analysis the following possible conflict of interest exists: (5a; 11)**

**section 2 (V) 2. Catalogue of potential conflicts of interest**

- (1) GBC AG or a legal person connected to them holds shares or other financial instruments of this company at the time of publication,
- (2) This company holds over 3 % of the shares in GBC AG or a legal person connected to them.
- (3) GBC AG or a legal person connected to them is a market maker or designated sponsor for the financial instruments of this company,
- (4) GBC AG or a legal person connected to them has, over the previous 12 months, organised or played a leading role in the public issue of financial instruments for this company.
- (5) a) GBC AG or a legal person connected to them has over the last 12 months agreed to create research reports for this company in return for payment, As part of this agreement the issuer was shown the draft of this analysis (excluding the evaluation section) prior to publication.
- (5) b) After receiving valid amendments by the analysed company, the draft of this analysis was changed.
- (6) a) GBC AG or a legal person connected to them has over the last 12 months agreed with a third party to create research reports about this company in return for payment, As part of this agreement the issuer was shown the draft of this analysis (excluding the evaluation section) prior to publication.
- (6) b) After receiving valid amendments by the third party, the draft of this analysis was changed.
- (7) The analyst responsible for this report holds shares or other financial instruments of this company at the time of publication,
- (8) The analyst responsible for this company is a member of the company's Executive Board or Supervisory Board.
- (9) The analyst responsible for this report received or purchased shares in the company analysed by said analyst, prior to the time of publication.
- (10) GBC or a related legal party has closed an agreement with the underlying company regarding consulting services during the previous 12 months.
- (11) GBC or a related legal party has a significant financial interest in the analysed company, for example to get mandated by the analysed company or to provide any kind of services (like the organization of fair, roundtables, road shows etc.).

**Section 2 (V) 3. Compliance**

GBC has defined internal regulatory measures in order to prevent potential conflicts of interest arising or, where they do exist, to declare them publicly. Responsibility for the enforcement of these regulations rests with the current Compliance Officer, Susanne Klebl, Email: [klebl@gbc-ag.de](mailto:klebl@gbc-ag.de)

**Section 2 (VI) Responsibility for report**

The company responsible for the creation of this/these analysis/analyses is GBC AG, with registered office in Augsburg, which is registered as a research institute with the responsible supervisory authority (Federal Financial Supervisory Authority or BaFin, Lurgiallee 12, 60439 Frankfurt, Germany).

GBC AG is currently represented by its board members Manuel Hölzle (Chairman), Jörg Grunwald and Christoph Schnabel,

The analysts responsible for this analysis are:

**Cosmin Filker, Dipl. Betriebswirt (FH), Finanzanalyst**  
**Manuel Hölzle, Dipl. Kaufmann, Chefanalyst**

**Section 3 Copyright**

This document is protected by copyright. It is made available to you solely for your information and may not be reproduced or distributed to any other person. Any use of this document outside the limits of copyright law shall, in principle, require the consent of GBC or of the relevant company, should the rights of usage and publication have been transferred.

GBC AG  
Halderstraße 27  
D 86150 Augsburg  
Tel.: 0821/24 11 33-0  
Fax.: 0821/24 11 33-30  
Internet: <http://www.gbc-ag.de>

E-Mail: [compliance@gbc-ag.de](mailto:compliance@gbc-ag.de)



